BrentD, MelhemN, FerrellR, EmslieG, WagnerKD, RyanN, VitielloB, BirmaherB, MayesT, ZelaznyJ, OnoratoM, DevlinB, ClarkeG, DeBar L KellerM: Association of FKBP5 polymorphisms with suicidal events in the treatment of resistant depression in adolescents (TORDIA) study. Am J Psychiatry, 167:190–197, 2010.
2.
GassóP, RodríguezN, MasS, PagerolsM, BlázquezA, PlanaMT, TorraM, LázaroL, LafuenteA: Effect of CYP2D6, CYP2C9 and ABCB1 genotypes on fluoxetine plasma concentrations and clinical improvement in children and adolescent patients. Pharmacogenomics J, 14:457–462, 2014.
3.
HicksJK, BishopJR, SangkuhlK, MullerDJ, JiY, LeckbandSG, LeederJS, GrahamRL, Chiulli DLLL, erenaA, SkaarTC, ScottSA, StinglJC, KleinTE, CaudleKE, GaedigkA: Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther, 98:127–134, 2015.
4.
PoweleitEA, AldrichSL, MartinLJ, HahnD, StrawnJR, RamseyLB: Pharmacogenetics of sertraline tolerability and response in pediatric anxiety and depressive disorders. J Child Adolesc Psychopharmacol, 29:348–361, 2019.
